Bradley Foster & Sargent Inc. CT Acquires 23,648 Shares of Becton, Dickinson and Company (NYSE:BDX)

Bradley Foster & Sargent Inc. CT boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 100.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 47,119 shares of the medical instruments supplier’s stock after buying an additional 23,648 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Becton, Dickinson and Company were worth $12,440,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Bank Julius Baer & Co. Ltd Zurich lifted its stake in Becton, Dickinson and Company by 98,105.4% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 6,929,375 shares of the medical instruments supplier’s stock worth $1,829,424,000 after purchasing an additional 6,922,319 shares during the last quarter. Providence Capital Advisors LLC lifted its stake in Becton, Dickinson and Company by 25,185.5% during the first quarter. Providence Capital Advisors LLC now owns 4,492,216 shares of the medical instruments supplier’s stock worth $18,147,000 after purchasing an additional 4,474,450 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its stake in Becton, Dickinson and Company by 95,813.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock worth $1,028,807,000 after purchasing an additional 4,041,425 shares during the last quarter. Norges Bank bought a new stake in Becton, Dickinson and Company during the fourth quarter worth about $697,398,000. Finally, BlackRock Inc. lifted its stake in Becton, Dickinson and Company by 5.7% during the first quarter. BlackRock Inc. now owns 23,794,080 shares of the medical instruments supplier’s stock worth $5,889,987,000 after purchasing an additional 1,281,866 shares during the last quarter. Institutional investors own 86.72% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP David Hickey sold 2,974 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $277.85, for a total transaction of $826,325.90. Following the transaction, the executive vice president now owns 4,199 shares in the company, valued at approximately $1,166,692.15. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Becton, Dickinson and Company news, EVP Richard Byrd sold 459 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $274.48, for a total transaction of $125,986.32. Following the transaction, the executive vice president now owns 3,444 shares in the company, valued at approximately $945,309.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Hickey sold 2,974 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $277.85, for a total value of $826,325.90. Following the transaction, the executive vice president now owns 4,199 shares in the company, valued at approximately $1,166,692.15. The disclosure for this sale can be found here. Insiders have sold a total of 4,281 shares of company stock worth $1,191,160 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.2 %

Shares of NYSE:BDX opened at $256.11 on Wednesday. Becton, Dickinson and Company has a 1 year low of $217.70 and a 1 year high of $287.32. The company has a market cap of $74.30 billion, a PE ratio of 46.46, a P/E/G ratio of 1.98 and a beta of 0.55. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.25 and a quick ratio of 0.73. The stock’s 50-day moving average is $262.37 and its 200 day moving average is $262.02.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Barclays lifted their price target on Becton, Dickinson and Company from $284.00 to $303.00 and gave the stock an “overweight” rating in a research note on Monday, August 7th. Morgan Stanley lifted their price target on Becton, Dickinson and Company from $295.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, August 4th. Raymond James decreased their price objective on Becton, Dickinson and Company from $305.00 to $304.00 and set an “outperform” rating on the stock in a report on Friday, August 4th. StockNews.com started coverage on Becton, Dickinson and Company in a report on Thursday, October 5th. They issued a “hold” rating on the stock. Finally, Piper Sandler lifted their price objective on Becton, Dickinson and Company from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, July 24th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $286.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.